본문 바로가기
KERD
논문KCI 등재

High Prevalence of Ceftazidime-Resistant Klebsiella pneumoniae and Increase of Imipenem-Resistant

김희준|이경원|용동은|정윤섭|임장현|조지현|어영|이위규
연세대학교의과대학 (Yonsei University College of Medicine)|2006.10|Yonsei Medical Journal|제47권 제5호|pp. 634-645

2

조회

0

다운로드

23

인용

0

참고문헌

주제분류의학일반

초록

A nationwide antimicrobial resistance surveillance has been conducted since 1997 in Korea. In this study, susceptibility test data generated in 2004 by KONSAR group hospitals were analyzed and compared to those at a commercial laboratory. In hospitals, the rank orders of organisms in 2004 were identical to those in 2003. The most prevalent species was Staphylococcus aureus (20.2%) in hospitals, but Escherichia coli (29.7%) in the commercial laboratory. The proportions of Enterococcus faecium to all isolates of Enterococcus faecalis plus E. faecium were 47.2% in hospitals and 24.9% in the commercial laboratory. The mean resistance rates of significant antimicrobial-organism combinations in hospitals were: oxacillin-resistant S. aureus (68%), oxacillin-resistant (penicillin- nonsusceptible) Streptococcus pneumoniae (68%), vancomycin-resistant E. faecium (25%), cefotaxime-resistant E. coli (14%), ceftazidime- and cefoxitin-resistant Klebsiella pneumoniae (34% and 32%, respectively), and imipenem-resistant Acinetobacter spp. and Pseudomonas aeruginosa (17% and 24%, respectively). In conclusion, oxacillin-resistant staphylococci, expanded-spectrum cephalosporin-resistant K. pneumoniae, and imipenem-resistant Acinetobacter spp. and P. aeruginosa were prevalent in 2004. Increasing trends were observed for vancomycin-resistant E. faecium, cefoxitin- resistant E. coli and K. pneumoniae, and imipenem-resistant Acinetobacter spp. and P. aeruginosa. Certain antimicrobial- organism combinations were also prevalent among the commercial laboratory-tested strains.

Abstract

A nationwide antimicrobial resistance surveillance has been conducted since 1997 in Korea. In this study, susceptibility test data generated in 2004 by KONSAR group hospitals were analyzed and compared to those at a commercial laboratory. In hospitals, the rank orders of organisms in 2004 were identical to those in 2003. The most prevalent species was Staphylococcus aureus (20.2%) in hospitals, but Escherichia coli (29.7%) in the commercial laboratory. The proportions of Enterococcus faecium to all isolates of Enterococcus faecalis plus E. faecium were 47.2% in hospitals and 24.9% in the commercial laboratory. The mean resistance rates of significant antimicrobial-organism combinations in hospitals were: oxacillin-resistant S. aureus (68%), oxacillin-resistant (penicillin- nonsusceptible) Streptococcus pneumoniae (68%), vancomycin-resistant E. faecium (25%), cefotaxime-resistant E. coli (14%), ceftazidime- and cefoxitin-resistant Klebsiella pneumoniae (34% and 32%, respectively), and imipenem-resistant Acinetobacter spp. and Pseudomonas aeruginosa (17% and 24%, respectively). In conclusion, oxacillin-resistant staphylococci, expanded-spectrum cephalosporin-resistant K. pneumoniae, and imipenem-resistant Acinetobacter spp. and P. aeruginosa were prevalent in 2004. Increasing trends were observed for vancomycin-resistant E. faecium, cefoxitin- resistant E. coli and K. pneumoniae, and imipenem-resistant Acinetobacter spp. and P. aeruginosa. Certain antimicrobial- organism combinations were also prevalent among the commercial laboratory-tested strains.

참고문헌 (48)

  1. "Antibiotic resistance surveillance: action for international studies", 49, pp.7~10 (2002)
  2. "Surveillance of antimicrobial resistance- what, how and whither?", 7, pp.316~325 (2001)
  3. "Aggregated antibiograms and monitoring of drug-resistant Streptococcus pneumoniae", 9, pp.1089~1095 (2003)
  4. "The Alexander Project: the benefit from a decade of surveillance", 56, pp.ii3~ii21 (2005)
  5. "European recommendations for antimicrobial resistance surveillance", 10, pp.349~383 (2004)
  6. "Korean nationwide surveillance of antimicrobial resistance of bacteria in 1997", 39, pp.569~577 (1998)
  7. "Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KONSAR surveillance", 47, pp.43~54 (2006)
  8. "VIM- and IMP-type metallo-β-lactamase-producing Pseudomonas spp. and Acinetobacter spp. in Korean hospitals.", 9, pp.868~871 (2003)
  9. "Prevalence of plasmid-mediated AmpC β-Lactamases in Escherichia coli and Klebsiella pneumoniae in Korea", 12, pp.44~49 (2006)
  10. "Evolution and epidemiology of extended-spectrum β-lactamases (ESBLs) and ESBL-producing microorganisms", 7, pp.597~608 (2001)
  11. "Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii", 36, pp.1268~1274 (2003)
  12. "Metallo-β-lactamases: the quiet before the storm?", 18, pp.306~325 (2005)
  13. "Analysis and presentation of cumulative antimicrobial susceptibility test data" (2002), NCCLS
  14. "Temporal changes in prevalence of antimicrobial resistance in 23 U.S. hospitals", 8, pp.697~701 (2002)
  15. "Surveillance of antimicrobial resistance: the WHONET program", 1, pp.157~168 (1997)
  16. "Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database-USA", 29, pp.259~263 (1999)
  17. "Performance Standards for antimicrobial susceptibility testing: fourteenth informational supplement" (2004), NCCLS
  18. "Epidemiological study of methicillin-resistant Staphylococcus aureus at Fukuoka University Hospital", 5, pp.207~213 (1999)
  19. "Methicillin- resistant Staphylococcus aureus in Europe, 1999-2002", 10, pp.1627~1634 (2004)
  20. "High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP Study)", 48, pp.2101~2107 (2004)
  21. "Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project", 51, pp.195~200 (2005)
  22. "The current status of surveillance of resistance to antimicrobial agents report on a meeting", 49, pp.17~23 (2002)
  23. "Nationwide antibiogram analysis using NCCLS M39-A guidelines", 43, pp.2629~2634 (2005)
  24. "Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002)", 43, pp.462~463 (2005)
  25. "Identification of CTX-M-14 extended-spectrum β-lactamase in clinical isolates of Shigella sonnei, Escherichia coli, and Klebsiella pneumoniae in Korea", 39, pp.3747~3749 (2001)
  26. "Molecular characterization of extended-spectrum beta-lactamases produced by clinical isolates of Klebsiella pneumoniae and Escherichia coli from a Korean nationwide survey", 42, pp.2902~2906 (2004)
  27. "Dissemination of SHV-12 and CTX-M-type extended-spectrum β-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae and emergence of GES-3 in Korea", 56, pp.698~702 (2005)
  28. "Regional variation in the prevalence of extended-spectrum β-lactamase- producing clinical isolates in the Asia-Pacific region (SENTRY 1998-2002)", 52, pp.323~329 (2005)
  29. "Prevalence and antimicrobial susceptibility data for extended-spectrum (-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997-2004)", 53, pp.257~264 (2005)
  30. "Occurrence and genotypic distribution of plasmid-mediated AmpC β-lactamase-producing Eshcherichia coli and Klebsiella pneumoniae in Korea", 22, pp.410~416 (2002)
  31. "Plasmid-mediated, inducible AmpC β-lactamase (DHA-1)-producing Enterobacteriaceae at a Korean hospital", 53, pp.65~70 (2005)
  32. "Plasmid-determined AmpC-type beta-lactamases", 46, pp.1~11 (2002)
  33. "In vivo transfer of plasmid-encoded ACC-1 AmpC from Klebsiella pneumoniae to Escherichia coli in an infant and selection of impermeability to imipenem in K", 49, pp.3562~3565 (2005)
  34. "Characterization of a new integron containing VIM-2 in a clinical isolate of Enterobacter cloacae", pp.397~400
  35. "Prevalence of decreased susceptibility to carbapenems among Serratia marcescens, Enterobacter cloacae, and Citrobacter freundii and investigation of carbapenemases", 52, pp.331~336 (2005)
  36. "In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains", 48, pp.1586~1592 (2004)
  37. "Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection", 54, pp.32~38 (2003)
  38. "Carbapenemases: a problem in waiting?", 3, pp.489~495 (2000)
  39. "Screening and identification of metallo-β-lactamase gene in clinical isolates of imipenem-resistant Pseudomonas aeruginosa", 24, pp.177~182 (2004)
  40. "Increasing prevalence of imipenem-resistant Pseudomonas aeruginosa and molecular typing of metallo-β-lactamase producers in a Korean hospital", 11, pp.355~359 (2005)
  41. "Imipenem-resistant Achromobacter xylosoxidans carrying blaVIM-2-containing class 1 integron", 53, pp.215~220 (2005)
  42. "Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 β-lactamase in Korea", 43, pp.2241~2245 (2005)
  43. "Polymyxin-resistant Acinetobacter spp. isolates; what is next?", 9, pp.1025~1027 (2003)
  44. "The future of the quinolones", 19, pp.1~5 (2001)
  45. "Characteristics of epidemic multidrugresistant Salmonella enterica serovar Typhimurium DT104 strains first isolated in Korea", 34, pp.1~8 (2002)
  46. "Rapidly increasing prevalence of β-lactamase-nonproducing, ampicillin-resistant Haemophilus influenzae type b in patients with meningitis", 48, pp.1509~1514 (2004)
  47. "The status of antimicrobial resistance in Taiwan among gram-negative pathogens", 48, pp.211~219 (2004)
  48. "Antimicrobial resistance trends and outbreak frequency in United States hospitals", 38, pp.78~85 (2004)

관련 논문AI추천

Increase of Ceftazidime- and Fluoroquinolone-Resistant Klebsiella pneumoniae and Imipenem-Resistant Acinetobacter spp. in Korea: Analysis of KONSAR Study Data from 2005 and 2007고은미, 김선주, 김진주, 노경호, 용동은, 이경원, 이미애, 이종욱, 이채훈, 정윤섭연세대학교의과대학 · Yonsei Medical Journal2010 · 제51권 제6호Further Increases in Carbapenem-, Amikacin-, and Fluoroquinolone-Resistant Isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR Study 2009강정옥, 김미나, 김재석, 박연준, 신종희, 용동은, 이경원, 장숙진, 정석훈, 홍혜림, The KONSAR Group, Yunsop Chong연세대학교의과대학 · Yonsei Medical Journal2011 · 제52권 제5호Increase in the Prevalence of Carbapenem-Resistant Acinetobacter Isolates and Ampicillin-Resistant Non- Typhoidal Salmonella Species김용근, 신희봉, 용동은, 이경원, 이위교, 정석훈, 정윤섭, 조지현, 최태열, 하경임대한감염학회 · Infection and Chemotherapy2014 · 제46권 제2호Comparison of Antibiotic Resistance Rate of Medically Important Microorganisms between Japan and Korea김선주, 이혁민, 케이고 시바야마대한임상미생물학회 · Annals of Clinical Microbiology2015 · 제18권 제4호Increasing Resistance to Extended-Spectrum Cephalosporins, Fluoroquinolone, and Carbapenem in Gram-Negative Bacilli and the Emergence of Carbapenem Non-Susceptibility in Klebsiella pneumoniae: Analysis of Korean Antimicrobial Resistance Monitoring System (KARMS) Data From 2013 to 2015김도균, 안지영, 용동은, 이경원, 이채훈, 이혁민, 장숙진, 정석훈대한진단검사의학회 · Annals of Laboratory Medicine2017 · 제37권 제3호2004년도 국내 12개 병원에서 분리된 주요 세균의 항균제 내성율어영, 김의종, 박연준, 신종희, 안지영, 용동은, 우건조, 이경원, 이성희, 이위교, 이종욱, 이혁민, 정석훈, 최태열, 홍성근대한임상미생물학회 · Annals of Clinical Microbiology2005 · 제8권 제1호

이 간행물의 다른 논문 (10건)

High Dose Chemotherapy and Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma: an Eight-Year Experience정준원, 장현, 한지숙pp. 604-613Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People강희철, 조희정, 윤방부, 이규래, 김경곤pp. 614-625The Effect of Fish Consumption on Blood Mercury Levels of Pregnant Women김인규, 김의혁, 김상운, 권자영, 박용원pp. 626-633White Blood Cell Count and the Risk of Colon Cancer이혜리, 지선하, 남정모, 황유경, 이용제pp. 646-656Soft Tissue Surgery for Equinus Deformity in Spastic Hemiplegic Cerebral Palsy: Effects on Kinematic and Kinetic Parameters박은숙, 김현우, 나동욱, 박창일pp. 657-666
원문 보기